XTL Biopharmaceuticals Ltd ADR (XTLB) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.38 (-0.42%), Market cap $0.01B, 52-week low–high $0.58 ~ $3.90.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ra
Financial statements, price targets, institutional (13F) holdings and related news for XTL Biopharmaceuticals Ltd ADR are updated in real time on BlackAll Trade.
XTL Biopharmaceuticals Ltd ADR trades at $2.38 (-0.42%). Real-time quotes and charts are available on BlackAll Trade.
XTL Biopharmaceuticals Ltd ADR has a market cap of about $0.01B.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate